¹**Circulating anti-Müllerian hormone levels in pre-menopausal women: novel genetic** ²**insights from a GWAS meta-analysis**

- 3 Natàlia Pujol-Gualdo#(1,2), Minna K. Karjalainen (3,4), Urmo Võsa (1), Riikka K. Arffman (2), 3)
4 Natedik Mägi (1), Justiina Ronkainen(3), Triin Laisk*(1), Terhi T. Piltonen*(2)
- ⁴Reedik Mägi (1), Justiina Ronkainen(3), Triin Laisk*(1), Terhi T. Piltonen*(2)
- 5 #first and corresponding author / *co-last authorship
- ⁶1. Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
- 7 2. Department of Obstetrics and Gynecology, Research Unit of Clinical Medicine, University
8 of Oulu. Oulu. Finland of Oulu, Oulu, Finland
- ⁹3. Research Unit of Population Health, Faculty of Medicine, University of Oulu, Oulu, Finland
- ¹⁰4. Northern Finland Birth Cohorts, Arctic Biobank, Infrastructure for Population Studies,
- 11 Faculty of Medicine, University of Oulu, Oulu, Finland

¹²**Abstract**

¹³**Study question:** Can a genome-wide association study (GWAS) meta-analysis, including a 14 large sample of young premenopausal women from a founder population from Northern
15 Finland, identify novel genetic variants for circulating anti-Müllerian hormone (AMH) levels 15 Finland, identify novel genetic variants for circulating anti-Müllerian hormone (AMH) levels
16 and provide insights into biological pathways and tissues involved in AMH regulation? and provide insights into biological pathways and tissues involved in AMH regulation?

Summary answer: We identified six loci associated with AMH levels at $P < 5 \times 10^{-8}$, 18 including the previously reported MCM8, AMH and TEX41 loci, and three novel signals in or 18 including the previously reported *MCM8*, *AMH* and *TEX41* loci, and three novel signals in or
19 near *CHEK2, BMP4* and *EIF4EBP1*, Gene set enrichment analysis highlighted significant 19 near *CHEK2*, *BMP4* and *EIF4EBP1*. Gene set enrichment analysis highlighted significant 10
10 enrichment in renal system vasculature morphogenesis and tissue enrichment analysis 20 enrichment in renal system vasculature morphogenesis and tissue enrichment analysis 21 ranks the pituitary aland as a top associated tissue. ranks the pituitary gland as a top associated tissue.

²²**What is known already:** AMH is expressed by preantral and small antral stage ovarian 23 follicles in women, and variation in age-specific circulating AMH levels has been associated
24 buith several health conditions. However, the biological mechanisms underlying the 24 with several health conditions. However, the biological mechanisms underlying the
25 association between health conditions and AMH levels are not yet fully understood. Previous 25 association between health conditions and AMH levels are not yet fully understood. Previous
26 GWAS have identified loci associated with AMH levels in pre-menopausal women, but they 26 GWAS have identified loci associated with AMH levels in pre-menopausal women, but they
27 were limited by small sample sizes or focused mostly on older pre-menopausal women. were limited by small sample sizes or focused mostly on older pre-menopausal women.

²⁸**Study design, size, duration:** We performed a GWAS meta-analysis for AMH level measurements in 9,668 pre-menopausal women.

³⁰**Participants/materials, setting, methods:** We performed a GWAS meta-analysis in which 31 we combined 2,619 AMH measurements (at age 31 years old) from a prospective founder
32 population cohort (Northern Finland Birth Cohort 1966, NFBC1966) with a previous GWAS 32 bopulation cohort (Northern Finland Birth Cohort 1966, NFBC1966) with a previous GWAS
33 meta-analysis that included 7.049 pre-menopausal women (spanning age range 15-48). 33 meta-analysis that included 7,049 pre-menopausal women (spanning age range 15-48).
34 DNFBC1966 AMH measurements were quantified using an automated assay (Elecsys® AMH 34 NFBC1966 AMH measurements were quantified using an automated assay (Elecsys® AMH
35 Plus (Roche)). We annotated the genetic variants, combined different data lavers to prioritise 35 Plus (Roche)). We annotated the genetic variants, combined different data layers to prioritise
36 Doptential candidate genes, described significant pathways and tissues enriched by the ³⁶potential candidate genes, described significant pathways and tissues enriched by the ³⁷GWAS signals, identified plausible regulatory roles using colocalization analysis and 38 leveraged publicly available summary statistics to assess genetic and phenotypic
39 correlations with multiple traits. correlations with multiple traits.

⁴⁰**Main results and the role of chance:** Three novel genome-wide significant loci were 41 identified. One of these is in complete linkage disequilibrium with c.1100delC in *CHEK2*,
42 which is found to be 4-fold enriched in the Finnish population compared to other European 42 which is found to be 4-fold enriched in the Finnish population compared to other European
43 Depulations. We propose a plausible regulatory effect of some of the GWAS variants linked 43 populations. We propose a plausible regulatory effect of some of the GWAS variants linked
44 b to AMH, as they colocalise with GWAS signals associated with gene expression levels of 44 to AMH, as they colocalise with GWAS signals associated with gene expression levels of
45 BMP4, TEX41 and EIFBP41. Gene set analysis highlighted significant enrichment in renal ⁴⁵*BMP4*, *TEX41* and *EIFBP41*. Gene set analysis highlighted significant enrichment in renal 46 system vasculature morphogenesis and tissue enrichment analysis ranked the pituitary
47 alandasthetopassociation. gland as the top association.

⁴⁸**Large scale data:** The GWAS meta-analysis summary statistics will be available for ⁴⁹download from the GWAS Catalog. Accession numbers will be provided upon publication.

⁵⁰**Limitations, reasons for caution:** This study only included women of European ancestry 51 and the unavailability of sufficiently sized relevant tissue data in gene expression datasets
52 binders the assessment of potential regulatory effects in reproductive tissues. hinders the assessment of potential regulatory effects in reproductive tissues.

⁵³**Wider implications of the findings:** Our results highlight the increased power of founder 54 bopulations and larger sample sizes to boost the discovery of novel trait-associated variants
55 bunderlying variation in AMH levels, which aided to characterise novel biological pathways 55 underlying variation in AMH levels, which aided to characterise novel biological pathways
56 and plausible genetic regulatory effects linked with AMH levels variation for the first time. and plausible genetic regulatory effects linked with AMH levels variation for the first time.

⁵⁷**Study funding / competing interest(s):** This work has received funding from the European 58 Union's Horizon 2020 research and innovation programme under the MATER Marie
59 Sklodowska-Curie grant agreement No. 813707 and Oulu university scholarship foundation 59 Sklodowska-Curie grant agreement No. 813707 and Oulu university scholarship foundation
60 (N.P.-G.), Academy of Finland, Sigrid Jusélius Foundation, Novo Nordisk, University of Oulu. 60 (N.P.-G.), Academy of Finland, Sigrid Jusélius Foundation, Novo Nordisk, University of Oulu,
61 Roche Diagnostics (T.T.P). This work was supported by the Estonian Research Council 61 Boche Diagnostics (T.T.P). This work was supported by the Estonian Research Council
62 arant 1911 (R.M.). J.R. was supported by the European Union's Horizon 2020 research and 62 brant 1911 (R.M.). J.R. was supported by the European Union's Horizon 2020 research and
63 bronovation program under grant agreements No. 874739 (LongITools), 824989 (EUCAN-63 innovation program under grant agreements No. 874739 (LongITools), 824989 (EUCAN-64 Connect), 848158 (EarlyCause) and 733206 (LifeCycle). U.V. was supported by the
65 Estonian Research Council grant PRG (PRG1291). The NFBC1966 received financial 65 Estonian Research Council grant PRG (PRG1291). The NFBC1966 received financial
66 support from University of Oulu Grant no. 24000692. Oulu University Hospital Grant no. 66 support from University of Oulu Grant no. 24000692, Oulu University Hospital Grant no.
67 24301140, ERDF European Regional Development Fund Grant no. 539/2010 A31592. ⁶⁷24301140, ERDF European Regional Development Fund Grant no. 539/2010 A31592.

⁶⁸**Keywords:** AMH; anti-Mullerian hormone, genome-wide association study, low-frequency variants, reproductive ageing

⁷⁰**INTRODUCTION**

71 Anti-Müllerian hormone (AMH) is a member of the transforming growth factor β (TGF-β)
72 Superfamily, which includes the bone morphogenic proteins (BMPs), growth differentiation 72 superfamily, which includes the bone morphogenic proteins (BMPs), growth differentiation
73 factors, activins and inhibins. Despite owing its name to its classical role in male sexual 73 factors, activins and inhibins. Despite owing its name to its classical role in male sexual
74 differentiation, AMH is also expressed by the ovarian granulosa cells during the primary to 74 brifferentiation, AMH is also expressed by the ovarian granulosa cells during the primary to
75 branall antral stage of follicle development (Weenen *et al.*, 2004). In adult women, serum 75 small antral stage of follicle development (Weenen *et al.*, 2004). In adult women, serum
76 AMH levels decrease with age, with undetectable levels following menopause, signalling 76 AMH levels decrease with age, with undetectable levels following menopause, signalling
77 depletion of ovarian reserve (Finkelstei *et al.*, 2020). As a result, AMH is primarily known as depletion of ovarian reserve (Finkelstei *et al.*, 2020). As a result, AMH is primarily known as

78 a serum marker for ovarian reserve. Previous studies have indicated that variations in age-79 specific circulating AMH levels are linked with several health conditions, including breast 70
180 cancer (Ge et al., 2018) and polycystic ovary syndrome (PCOS) (Homburg and Crawford, 80 cancer (Ge *et al.*, 2018) and polycystic ovary syndrome (PCOS) (Homburg and Crawford, 81 2014). Therefore, identifying genetic determinants of inter-individual variation in AMH 81 2014). Therefore, identifying genetic determinants of inter-individual variation in AMH
82 measurements may offer valuable insight into their biological mechanistic effects and impact 82 measurements may offer valuable insight into their biological mechanistic effects and impact 83 in health and disease bevond reproductive ageing. in health and disease beyond reproductive ageing.

84 Three previous genome-wide association studies have identified a few loci associated with
85 AMH levels in pre-menopausal women (Schuh-Huerta et al., 2012; Ruth et al., 2019; ⁸⁵AMH levels in pre-menopausal women (Schuh-Huerta *et al.*, 2012; Ruth *et al.*, 2019; 86 Verdiesen *et al.*, 2022). However, these studies were limited by small sample size (Schuh-⁸⁷Huerta *et al.*, 2012) or focusing only or mostly on older pre-menopausal women (Ruth *et al.*, 88 2019; Verdiesen *et al.*, 2022). Since AMH decreases with age also the AMH variability
89 decreases in older ages, and therefore there is less power to detect associations in older 89 decreases in older ages, and therefore there is less power to detect associations in older
80 pre-menopausal women compared to vounger pre-menopausal women. To address these 90 pre-menopausal women compared to younger pre-menopausal women. To address these
91 limitations, our current work analyses data from a single time point measured in relatively 91 limitations, our current work analyses data from a single time point measured in relatively
92 voung pre-menopausal women and combines this dataset with a previous meta-analysis 92 young pre-menopausal women and combines this dataset with a previous meta-analysis
93 (Verdiesen et al., 2022), to identify and characterise additional loci associated with AMH ⁹³(Verdiesen *et al.*, 2022), to identify and characterise additional loci associated with AMH levels in pre-menopausal women.

95 The studies conducted so far have focused on European ancestry, mainly powered to 96 discover associations with common genetic variants. Nonetheless, founder populations such 96 discover associations with common genetic variants. Nonetheless, founder populations such
97 as those found in northern Finland, represent a powerful resource to accelerate discovery of 97 as those found in northern Finland, represent a powerful resource to accelerate discovery of 98 new biological mechanisms driven by low-frequency alleles that have risen to higher 98 new biological mechanisms driven by low-frequency alleles that have risen to higher
99 frequency due to unique demographic history (Kurki et al., 2023). frequency due to unique demographic history (Kurki *et al.*, 2023).

100 In the present study, we added 2,619 AMH measurements (at age 31 years old) from a
101 prospective founder population cohort (Northern Finland Birth Cohort 1966, NFBC1966) to a 101 prospective founder population cohort (Northern Finland Birth Cohort 1966, NFBC1966) to a
102 previous GWAS meta-analysis of 7.049 pre-menopausal women (spanning age range 15-102 previous GWAS meta-analysis of 7,049 pre-menopausal women (spanning age range 15-
103 48) (Verdiesen et al., 2022), reaching the largest sample size for assessing AMH variation in 103 48) (Verdiesen *et al.*, 2022), reaching the largest sample size for assessing AMH variation in
104 women from reproductive age to date (N=9.668). Bevond detecting three out of the four 104 women from reproductive age to date $(N=9,668)$. Beyond detecting three out of the four 105 previously identified signals near $TEX41$, $MCM8$ and AMH , we identified three novel signals 105 previously identified signals near *TEX41*, *MCM8* and *AMH*, we identified three novel signals
106 pear *EIF4EBP1, BMP4,* and *CHEK*2, In the *CHEK2* locus, the c.1100delC variant is enriched 106 near *EIF4EBP1, BMP4*, and *CHEK2*. In the *CHEK2* locus, the c.1100delC variant is enriched
107 in the Finnish population and in complete linkage disequilibrium (r²=1) with the lead variant 107 in the Finnish population and in complete linkage disequilibrium $(r^2=1)$ with the lead variant 108 identified in that locus. Additionally, we tested requilatory effects of GWAS variants on 108 identified in that locus. Additionally, we tested regulatory effects of GWAS variants on
109 specific genes and gene transcript expression in multiple tissues using colocalization 109 specific genes and gene transcript expression in multiple tissues using colocalization
110 analysis, evaluated gene set and tissue set enrichments, and estimated genetic correlations 110 analysis, evaluated gene set and tissue set enrichments, and estimated genetic correlations
111 and phenotypic associations across multiple phenotypes, by leveraging publicly available 111 and phenotypic associations across multiple phenotypes, by leveraging publicly available 112 summary statistics. summary statistics.

¹¹³**METHODS**

¹¹⁴**Study design and setting**

115 116 This study is based on the prospective population-based NFBC1966 study (University of 117 Oulu. 1966. http://urn.fi/urn.rbn.fi/att:bc1e5408-980e-4a62-b899-43bec3755243). During 117 Oulu, 1966, http://urn.fi/urn:nbn:fi:att:bc1e5408-980e-4a62-b899-43bec3755243). During
118 1966. 12231 children (of them 5.889 females) were born in the two northernmost provinces 118 1966, 12231 children (of them 5,889 females) were born in the two northernmost provinces
119 of Finland (covering 48% of Finnish territory). Originally, the study was set to evaluate early 119 of Finland (covering 48% of Finnish territory). Originally, the study was set to evaluate early
120 life factors on long-term health and work ability. The cohort population has been followed up 120 life factors on long-term health and work ability. The cohort population has been followed up
121 at four different time points: 1, 14, 31 and 46 years of age (set by the cohort centre). 121 at four different time points: 1, 14, 31 and 46 years of age (set by the cohort centre).
122 Comprehensive questionnaires on female health and clinical examinations with biological 122 Comprehensive questionnaires on female health and clinical examinations with biological
123 data collection were performed at ages 31 and 46 years. 123 data collection were performed at ages 31 and 46 years.
124

124

125 The detailed cohort description and follow up protocol has been previously published
126 (Nordström et al., 2022). Briefly, in 1997 (the 31-vear follow-up) women living in the Northern ¹²⁶(Nordström *et al.*, 2022). Briefly, in 1997 (the 31-year follow-up) women living in the Northern 127 Finland area or in the Helsinki metropolitan area (n=4074 women) were invited to a clinical
128 examination, in which 3,127 (77%) women participated. The present study includes 2,619 128 examination, in which 3,127 (77%) women participated. The present study includes 2,619
129 women with AMH and genetic data available at 31 years old (median=31.1, interquartile 129 women with AMH and genetic data available at 31 years old (median=31.1, interquartile 130 range (IQR)=30.9-31.4). 130 range (IQR)=30.9-31.4).
131

132 132 For the meta-analysis, publicly available summary statistics from an independent second
133 study evaluating AMH variations across 7.049 pre-menopausal women were used 133 study evaluating AMH variations across 7,049 pre-menopausal women were used
134 (Verdiesen et al., 2022). Publicly available summary statistics were downloaded from the ¹³⁴(Verdiesen *et al.*, 2022). Publicly available summary statistics were downloaded from the 135 GWAS catalog (https://www.ebi.ac.uk/gwas/publications/35274129) under accession
136 number GCST90104596. This study included data from the AMH GWAS meta-analysis by 136 number GCST90104596. This study included data from the AMH GWAS meta-analysis by
137 Ruth *et al.* (n=3.334) (Ruth *et al.*, 2019), which meta-analysed four studies, and three 137 Ruth *et al.* (n=3,334) (Ruth *et al.*, 2019), which meta-analysed four studies, and three
138 cohorts which were additionally analysed and ioined to the latter, conforming the most recent 138 cohorts which were additionally analysed and joined to the latter, conforming the most recent 139 meta-
139 meta-analysis (n=7,049) (Verdiesen *et al.,* 2022). The cohort details from the current meta-139 meta-analysis (n=7,049) (Verdiesen *et al.*, 2022). The cohort details from the current meta-140 analysis (n=9,668) can be found in Supplementary Table 1. More details of cohort 141 description of the studies included can be found in (Verdiesen *et al.*, 2022). All studies had 141 description of the studies included can be found in (Verdiesen *et al.*, 2022). All studies had 142 received ethical approval from institutional ethics committees. 142 received ethical approval from institutional ethics committees.
143

-
- 143

145 ¹⁴⁵**AMH measurement in NFBC1966**

146 Serum samples were drawn in 1997 (the 31-year follow up), sealed and stored at −20℃
147 Since then. Serum AMH concentrations were measured using the automated Elecsys® since then. Serum AMH concentrations were measured using the automated Elecsys® 148 electrochemiluminescence immunoassay on a Cobas E411 analyser according to the 149 manufacturer's instructions (Roche Diagnostics, Germany). More detailed information on 150 AMH measurement has been published previously (Piltonen et al., 2023). AMH measurement has been published previously (Piltonen *et al.*, 2023).

151 The assay limits of detection and quantitation were 0.01 ng/ml and 0.03 ng/ml for AMH.
152 Intra- and inter-assay coefficients of variance were 1.0–1.8% and 2.9–4.4% for AMH. Limits 152 Intra- and inter-assay coefficients of variance were 1.0–1.8% and 2.9–4.4% for AMH. Limits 153 above the measuring ranges were 23 ng/ml for AMH. above the measuring ranges were 23 ng/ml for AMH.

154 AMH concentrations were converted to pmol/l using 1 ng/ml = 7.14 pmol/l. As AMH levels
155 are not normally distributed, for the following analysis AMH measurements were transformed 155 are not normally distributed, for the following analysis AMH measurements were transformed
156 using rank-based inverse normal transformation, as done previously (Ruth *et al.,* 2019). For 156 using rank-based inverse normal transformation, as done previously (Ruth *et al.*, 2019). For 157
157 rank-based inverse normal transformation we used the package *RNOmni* in R v3.6.3.

rank-based inverse normal transformation we used the package *RNOmni* in R v3.6.3.

¹⁵⁸**Genotyping details and association analysis**

159 Genotyping of the NFBC1966 samples was performed with the Illumina Infinium
160 HumanCNV370-Duo array. Samples were excluded based on call rate < 9 160 HumanCNV370-Duo array. Samples were excluded based on call rate < 95%, gender
161 mismatch, relatedness (identity by descent (IBD) estimate pihat>0.2) and outlying 161 mismatch, relatedness (identity by descent (IBD) estimate pihat>0.2) and outlying
162 heterozygosity, SNPs were excluded based on missingness rate >5%, HWE p <0.000001 162 heterozygosity. SNPs were excluded based on missingness rate >5%, HWE p <0.000001
163 and MAF <1%. Genotypes were imputed with Beagle 4.1 using the SiSu v3 imputation 163 and MAF <1%. Genotypes were imputed with Beagle 4.1 using the SiSu v3 imputation
164 Freference panel, which consisted of 3775 individuals of Finnish ancestry with sequenced 164 reference panel, which consisted of 3775 individuals of Finnish ancestry with sequenced 165 whole genomes. 165 whole genomes.
166

167 167 Association analysis was performed using SNPTEST v2.5.4-beta1, adjusted by the first 10
168 Genetic principal components. Markers with INFO score >0.4 were kept for the meta-168 genetic principal components. Markers with INFO score >0.4 were kept for the metaanalysis. Positions were converted to build hg37 to harmonise the data with the summary

170 statistics available from Verdiesen *et al.* before running the meta-analysis, using LiftOver
171 (Kent e*t al.* 2002). ¹⁷¹(Kent *et al.*, 2002).

¹⁷³**GWAS meta-analysis**

174 We conducted an inverse variance weighted fixed-effects meta-analysis with single genomic
175 control correction using GWAMA software (v2.2.2) (Mägi and Morris, 2010). A total of 175 control correction using GWAMA software (v2.2.2) (Mägi and Morris, 2010). A total of 168.
176 13.903.812 variants were included in the meta-analysis of 9.688 AMH measurements. After 176 13,903,812 variants were included in the meta-analysis of 9,688 AMH measurements. After
177 meta-analysis we kept variants present in both studies (totalling 7,900,839 variants) for 177 meta-analysis we kept variants present in both studies (totalling 7,900,839 variants) for
178 downstream analysis. Lead SNPs were identified as SNVs independent from each other 178 downstream analysis. Lead SNPs were identified as SNVs independent from each other 179 with P-value less than or equal to $5\square \times \square 10^{-8}$. The maximum distance between LD blocks of 179 with *P*-value less than or equal to 5⊡x⊟10⁻⁸. The maximum distance between LD blocks of 100 and the maximum distance between LD blocks of 180 independent SNPs to merge into a single genomic locus was set to 500 \square kb.

¹⁸¹**Heritability analysis**

182 The heritability (h²) was estimated by single-trait LD score regression using the meta-
183 analysis summary statistics and HapMap 3 LD-scores using LDSC v1.0.1 183 analysis summary statistics and HapMap 3 LD-scores using LDSC v1.0.1
184 (https://aithub.com/bulik/Idsc)(Bulik-Sullivan et al., 2015). ¹⁸⁴(https://github.com/bulik/ldsc) (Bulik-Sullivan *et al.*, 2015).

¹⁸⁵**Annotation of GWAS signals**

186 We used FUMA (v1.4.0) to annotate the GWAS signals (Watanabe *et al.*, 2017). FUMA is an 187 online platform that performs annotation of GWAS signals using data from several 187 online platform that performs annotation of GWAS signals using data from several
188 databases. First. FUMA identifies lead SNPs (p-value $\lt = 5 \times 10^{-8}$ and SNP pairwise LD 188 databases. First, FUMA identifies lead SNPs (p-value <=5 x 10⁻⁸ and SNP pairwise LD
189 r2<0.1, based on 1000G European reference) and independent significant SNPs and each 189 r2<0.1, based on 1000G European reference) and independent significant SNPs and each
190 risk locus (p-value <5 x 10⁻⁸ and LD r2< 0.6) (Supplementary Table 2). Then FUMA risk locus (p-value <5 x 10⁻⁸ and LD r2< 0.6) (Supplementary Table 2). Then FUMA
191 identifies potential candidate SNPs that are in LD with anv of the identified independent 191 identifies potential candidate SNPs that are in LD with any of the identified independent
192 significant SNPs and annotates them via linking with several databases (ANNOVAR, 192 significant SNPs and annotates them via linking with several databases (ANNOVAR,
193 RegulomeDB, CADD scores etc.), which gives information on their location, functional 193 RegulomeDB, CADD scores etc.), which gives information on their location, functional 194 impact and potential regulatory effects. 194 impact, and potential regulatory effects.
195

195

197 ¹⁹⁷**Colocalization analysis**

198 ¹⁹⁹We used HyPrColoc (Foley *et al.*, 2021), a colocalisation method for identifying the overlap 200 between our GWAS meta-analysis signals and cis-quantitative trait loci (cis-QTL) signals
201 from different tissues and cell types (expression QTLs, transcript QTLs, exon QTLs and 201 from different tissues and cell types (expression QTLs, transcript QTLs, exon QTLs and 202 exon usage QTLs available in the eQTL Catalogue (Kerimov et al., 2021)). We lifted the 202 exon usage QTLs available in the eQTL Catalogue (Kerimov *et al.*, 2021)). We lifted the 203 CWAS summary statistics over to ha38 build to match the eQTL Catalogue using binary 203 GWAS summary statistics over to hg38 build to match the eQTL Catalogue using binary
204 liftOver tool (https://genome.sph.umich.edu/wiki/LiftOver#Binary liftOver tool). liftOver tool (https://genome.sph.umich.edu/wiki/LiftOver#Binary_liftOver_tool).

For the genome-wide significant ($p \le 5 \times 10^{-8}$) GWAS loci identified we extracted the $+/-$
206 500kb of its top hit from QTL datasets and ran the colocalization analysis against eQTL 206 500kb of its top hit from QTL datasets and ran the colocalization analysis against eQTL
207 Catalogue traits. For each eQTL Catalogue dataset we included all the QTL features which 207 Catalogue traits. For each eQTL Catalogue dataset we included all the QTL features which
208 Shared at least 80% of tested variants with the variants present in our GWAS region. We 208 shared at least 80% of tested variants with the variants present in our GWAS region. We
209 used the default settings for HyPrColoc analyses and did not specify any sample overlap 209 used the default settings for HyPrColoc analyses and did not specify any sample overlap
210 argument, because HyPrColoc paper (Foley et al., 2021) demonstrates that assuming trait 210 argument, because HyPrColoc paper (Foley *et al.*, 2021) demonstrates that assuming trait 211 independence gives reasonable results. HyPrColoc outputs the posterior probability that 211 independence gives reasonable results. HyPrColoc outputs the posterior probability that 212 oenetic association signals for those traits are colocalising (we considered two or more ²¹²genetic association signals for those traits are colocalising (we considered two or more

213 signals to colocalize if the posterior probability for a shared causal variant (PP4) was 0.8 or 214 bight
214 bigher). All results with a PP4 > 0.8 can be found in Supplementary Table 3. higher). All results with a PP4 > 0.8 can be found in Supplementary Table 3.

²¹⁵**Gene prioritization**

216 In order to nominate plausible candidate genes in each locus, we prioritized genes according
217 to different levels of evidence: (1) genes containing lead variants that are coding variants or 217 to different levels of evidence: (1) genes containing lead variants that are coding variants or 218 coding variants in high LD ($r2\square > \square 0.6$) with lead variants; (2) genes whose expression was 218 – coding variants in high LD (r2⊡>⊡0.6) with lead variants; (2) genes whose expression was
219 – requiated by eOTL variants that showed significant (posterior probability S0.8) colocalization. 219 regulated by eQTL variants that showed significant (posterior probability >0.8) colocalization
220 vith our GWAS signals: (3) genes which showed a plausible biological role as defined 220 with our GWAS signals; (3) genes which showed a plausible biological role as defined 221 previously in the research literature. previously in the research literature.

²²²**Gene set and tissue set enrichment analysis**

223 Gene set enrichment analysis and tissue set enrichment analysis were performed using
224 MAGMA v1.08 implemented in FUMA v1.4.0. Gene sets were obtained from Msigcbv7.0 for 224 MAGMA v1.08 implemented in FUMA v1.4.0. Gene sets were obtained from Msigcbv7.0 for
225 Curated gene sets' and 'GO terms'. A total of 15.485 gene terms were queried. The results 225 Curated gene sets' and 'GO terms'. A total of 15,485 gene terms were queried. The results
226 of this analysis are presented in Supplementary Table 4 and Supplementary Figure 2. 226 of this analysis are presented in Supplementary Table 4 and Supplementary Figure 2.
227 Tissue expression analysis was performed for 53 tissue types using MAGMA. The results of 227 Tissue expression analysis was performed for 53 tissue types using MAGMA. The results of 2.
228 This analysis are presented in Supplementary Table 5 and Supplementary Figure 2. this analysis are presented in Supplementary Table 5 and Supplementary Figure 2.

²²⁹**Genetic correlation analysis**

230 The Complex Traits Genetics Virtual Lab (CTG-VL, https://vl.genoma.io/) was used to
231 calculate genetic correlations between the AMH meta-analysis and 1335 traits. We applied a 231 calculate genetic correlations between the AMH meta-analysis and 1335 traits. We applied a
232 multiple testing correction (Beniamini-Hochberg FDR < 5%) to determine statistical 232 multiple testing correction (Benjamini-Hochberg FDR \lt 5%) to determine statistical 233 significance using the *p.adiust* function in R 3.6.3. Results of the genetic correlation analysis 233 significance using the *p.adjust* function in R 3.6.3. Results of the genetic correlation analysis 234 are presented in Supplementary Figure 3 and Supplementary Figure 234 are presented in Supplementary Figure 3 and Supplementary Table 6.
235

235 ²³⁶**Phenome-wide associations**

238 238 We evaluated the association of our GWAS lead variants and variants in high LD with these
239 by using human health traits and phenotypes available in the GWAS Catalog (e0 r2022-11-239 by using human health traits and phenotypes available in the GWAS Catalog (e0_r2022-11-
240 29) as implemented in FUMA. We also gueried the lead variants of this study from the 240 29) as implemented in FUMA. We also queried the lead variants of this study from the 241 FinnGen study (data freeze 9. total n=377.277), which combines samples collected from 241 FinnGen study (data freeze 9, total n=377,277), which combines samples collected from
242 Finnish biobanks to digital health care data (Kurki *et al.*, 2023). The results obtained are 242 Finnish biobanks to digital health care data (Kurki *et al.*, 2023). The results obtained are 243 found in Supplementary Table 7 and 8 and Supplementary Table 7 and and Supplementary Table 7 and Supplementary Table 7 a 243 found in Supplementary Table 7 and 8 and Supplementary Figure 4.
244

-
- 245
- 245 247
- 248
- 248
- 250

250 ²⁵¹**RESULTS**

252

²⁵³**Genome-wide association study for AMH levels**

254 To detect genetic factors associated with circulating AMH levels, we performed a GWAS
255 meta-analysis with data from two studies (NFBC1966 GWAS and summary statistics publicly meta-analysis with data from two studies (NFBC1966 GWAS and summary statistics publicly

- 256 available from Verdiesen *et al.,* 2022 including a total of 9,668 AMH measurements 257 guantified from women of pre-menopausal age and European ancestry. 257 quantified from women of pre-menopausal age and European ancestry.
258 The meta-analysis identified a total of six associated loci, with six
-
- 258 The meta-analysis identified a total of six associated loci, with six independent signals
259 significantly associated with AMH levels ($P\square < \square 5\square \times \square 10^{-8}$) (Table 1, Supplementary Figure 259 significantly associated with AMH levels (*P*□<=□5□×□10⁻⁸) (Table 1, Supplementary Figure
- 260 1). A total of 70 SNPs reached genome-wide significance (*P*□<=□5□×□10⁻⁸).

262
263

Supplementary Figure 1. Regional plots showing the six independent loci significantly
 264 associated with AMH levels. Plots were created using the LocusZoom tool 264 **associated with AMH levels.** Plots were created using the LocusZoom tool 265 (locuszoom.org). The y axis represents -log₁₀(P-values) for association of variants with AMH (locuszoom.org). The *y* axis represents -log₁₀(*P*-values) for association of variants with AMH

266 levels and the *x* axis represents the chromosomal positions of the variants. Each lead variant 267 is shown as a purple diamond in each of the six genetic loci defined. is shown as a purple diamond in each of the six genetic loci defined.

Table 1. Genome-wide significant signals (p <= 5 x 10-8 ²⁶⁸**) in the meta-analysis for inverse normally transformed anti-Müllerian hormone levels in women. SNPs showing the most significant associations at each locus are shown, and novel genome-wide significant signals are highlighted in bold. EUR; European (non-Finnish), FINN:**

European (Finnish)

274

275
276 276 Three of the associated loci were previously reported and were located in or near *AMH*
277 Tre10417628 n=9.34 x 10⁻⁰⁹) TEX41 (re6729614 n=1.68 x 10⁻¹⁰) and *MCM8* (re16991615 (rs10417628, p=9.34 × 10-09), *TEX41* (rs6729614, p=1.68 × 10-10 ²⁷⁷) and *MCM8* (rs16991615, p=4.68× 10-09 ²⁷⁸) (Ruth *et al.*, 2019; Verdiesen *et al.*, 2022), and three of the associated loci were novel. The novel loci included associations near *EIF4EBP1* (rs10093345, p=9.34 x 10⁻ 279)
280 ⁰⁹ *BMP4 (rs762643 p=1.98x 10⁻⁰⁹) and CHEK2 (rs186430430 p=9.69 x 10⁻¹¹) (see Figure* 0^{09}), *BMP4* (rs762643, p=1.98 \times 10⁻⁰⁹) and *CHEK2* (rs186430430, p=9.69 \times 10⁻¹¹) (see Figure
281 1. Table 1). All lead variants were present in the two datasets analysed, and the directions of 281 1, Table 1). All lead variants were present in the two datasets analysed, and the directions of 282 effects were consistent between the datasets for all six lead variants (Figure 2). effects were consistent between the datasets for all six lead variants (Figure 2).

283 There was no evidence of excessive genomic inflation (λ□=□1.01) in the GWAS meta-
284 analysis (LDSC intercent− 1.0039 (s.e. 0.0076)). The observed scale SNP beritability 284 analysis (LDSC intercept= 1.0039 (s.e. 0.0076)). The observed scale SNP heritability 285 estimate was 0.13 (s.e. 0.05). estimate was 0.13 (s.e. 0.05).

286
287

292

287 **Figure 1. Manhattan plot for GWAS meta-analysis for AMH levels in pre-menopausal**
288 **women (n=9,668)**. The novel loci are highlighted in blue. The y axis represents -log₁₀(*P*-288 **women (n=9,668)**. The novel loci are highlighted in blue. The *y* axis represents −log₁₀(P-
289 values) for association of variants with AMH levels and the *x* axis represents the 289 values) for association of variants with AMH levels and the *x* axis represents the
290 chromosomal positions of the variants. The red horizontal dashed line represents the 290 chromosomal positions of the variants. The red horizontal dashed line represents the 291 threshold for genome-wide significance $(P \square \le \square 5 \square \times \square 10^{-8})$. 291 threshold for genome-wide significance (*P*□<□5□×□10⁻⁸).

293
294 ²⁹⁴**Figure 2. Forest plot of effect estimates for the 6 lead variants associated with AMH** ²⁹⁵**levels across datasets meta-analysed.** The betas and standard errors are shown for the 296 two studies meta-analysed (NFBC1966 (green dots, *n*=2,619), Verdiesen *et al.* (orange dots, 297 n=7,049), and the presented largest meta-analysis (Meta-analysis, purple dots, n=9,668). ²⁹⁷*n*=7,049), and the presented largest meta-analysis (Meta-analysis, purple dots, *n*=9,668). 298 Candidate genes are also shown next to each genetic lead signal. Betas represent the effect
299 sizes of each genetic variant association to phenotype, assessing the same risk allele across 299 sizes of each genetic variant association to phenotype, assessing the same risk allele across
300 cohorts (Effect allele and effect allele frequency are reported in Table 1). cohorts (Effect allele and effect allele frequency are reported in Table 1).

³⁰²**Characterisation of GWAS signals**

303 Two out of the six lead variants that were detected are non-synonymous, making them
304 notably easier to interpret and establishing a more solid foundation for pinpointing potential 304 notably easier to interpret and establishing a more solid foundation for pinpointing potential
305 candidate genes. These non-synonymous variants are found in *AMH (A*nti-Mullerian 305 candidate genes. These non-synonymous variants are found in *AMH* (Anti-Mullerian
306 Hormone) (rs10417628 in chromosome 19. p=9.56 x 10⁻¹²) and *MCM8* (Minichromosome 306 Hormone) (rs10417628 in chromosome 19, p=9.56 x 10⁻¹²) and *MCM8* (Minichromosome 30, 307 Maintenance 8 Homologous Recombination Repair Factor) (rs16991615 in chromosome 20, 307 Maintenance 8 Homologous Recombination Repair Factor) (rs16991615 in chromosome 20, 308 $p=4.68 \times 10^{09}$) and were previously described to be associated with AMH levels (Ruth *et al..*) 308 $p=4.68 \times 10^{-09}$) and were previously described to be associated with AMH levels (Ruth *et al.*, 309 $\,$ 2019; Verdiesen *et al.*, 2022). ³⁰⁹2019; Verdiesen *et al.*, 2022).

310 In the novel locus identified on chromosome 22, the lead variant is an intronic variant near
311 *CHEK2* (Checkpoint Kinase 2) (rs186430430, p=9.69 x 10⁻¹¹), Interestingly, this variant is in 311 *CHEK2* (Checkpoint Kinase 2) (rs186430430, p=9.69 \times 10⁻¹¹). Interestingly, this variant is in 312 complete linkage disequilibrium (r^2 =1) with the frameshift variant c.1100delC in *CHEK2* complete linkage disequilibrium $(r^2=1)$ with the frameshift variant c.1100delC in *CHEK2*
313 (rs555607708). Despite complete linkage disequilibrium, this rare variant is only found in the 313 (rs555607708). Despite complete linkage disequilibrium, this rare variant is only found in the 314 association analysis of the NFBC1966 GWAS, showing a p-value of 6.69 \times 10⁻⁰⁵ and beta of 314 association analysis of the NFBC1966 GWAS, showing a p-value of 6.69 \times 10⁻⁰⁵ and beta of 315 0.79 (s.e=0.12) in this cohort only and not found in the summary statistics results from 315 0.79 (s.e=0.12) in this cohort only and not found in the summary statistics results from 316 Verdiesen et al , likely explained by the fact that this variant is enriched in the Finnish 316 Verdiesen *et al.*, likely explained by the fact that this variant is enriched in the Finnish
317 population (MAF= 0.008) compared to other European populations (MAF=0.002), and thus 317 population (MAF= 0.008) compared to other European populations (MAF=0.002), and thus 318 better powered to be captured in a GWAS setting including the former population in the 318 better powered to be captured in a GWAS setting including the former population in the 319 analysis. analysis.

320 For the other three loci identified on chromosomes 2, 8 and 14, we defined for the first time
321 plausible shared causal variants between GWAS signals and transcript and gene expression 321 plausible shared causal variants between GWAS signals and transcript and gene expression
322 in specific tissues by colocalization analysis. This resulted in the prioritisation of three 322 in specific tissues by colocalization analysis. This resulted in the prioritisation of three
323 plausible candidate genes, respectively: *TEX41* (Testis Expressed 41), *EIF4EBP1* 323 plausible candidate genes, respectively: *TEX41* (Testis Expressed 41), *EIF4EBP1*
324 (Eukaryotic Translation Initiation Factor 4E Binding Protein 1) and *BMP4* (Bone ³²⁴(Eukaryotic Translation Initiation Factor 4E Binding Protein 1) and *BMP4* (Bone Morphogenetic Protein 4) (Supplementary Table 3).

326 For instance, the association signal in chromosome 2, in an intronic region of *TEX41*,
327 colocalized with eQTL signals for *TEX1* transcripts ENST00000414256 in the testis 327 colocalized with eQTL signals for *TEX1* transcripts ENST00000414256 in the testis
328 (PP4=0.99) and ENST00000445791 in the skin (PP4=1). *EIF4EBP1* was also prioritised ³²⁸(PP4=0.99) and ENST00000445791 in the skin (PP4=1). *EIF4EBP1* was also prioritised 329 based on colocalization evidence in three tissues, with high colocalization probability
330 (PP4=0.90) between the GWAS signal and cis-eQTLs for *EIF4EBP1* expression in brain ³³⁰(PP4=0.90) between the GWAS signal and cis-eQTLs for *EIF4EBP1* expression in brain 331 frontal cortex tissue, and between the GWAS signal and cis-eQTLs for *EIF4EBP1* **332** expression in left heart ventricle. Additionally, the GWAS association signal in chromosome 332 expression in left heart ventricle. Additionally, the GWAS association signal in chromosome
333 8 showed colocalization with cis-eQTLs for *BMP4* transcripts ENST00000245451 and 333 8 showed colocalization with cis-eQTLs for *BMP4* transcripts ENST00000245451 and
334 ENST00000558489 in colon transverse (PP4=0.84) and *BMP4* transcript ³³⁴ENST00000558489 in colon transverse (PP4=0.84) and *BMP4* transcript ³³⁵ENST00000558489 in tibial nerve.

336 From colocalization results, only in the locus of chromosome 2, we observed that the 337 associations might be explained by a single variant. Namely, we observed that the non-337 associations might be explained by a single variant. Namely, we observed that the non-
338 coding transcript (TEX41) exon variant rs17407477 and the intronic variant rs786244 were 338 coding transcript (*TEX41*) exon variant rs17407477 and the intronic variant rs786244 were
339 explaining most of the shared association, for the testis transcript expression association 339 explaining most of the shared association, for the testis transcript expression association
340 (posterior inclusion probability 0.90) and the skin transcript expression association (posterior 340 (posterior inclusion probability 0.90) and the skin transcript expression association (posterior 341 inclusion probability 0.94), respectively. inclusion probability 0.94), respectively.

342 Although we identified three out of the four signals that were previously reported in 343 Verdiesen et al., 2022, we were unable to detect the signal near CDCA7 described in the 343 Verdiesen *et al.*, 2022, we were unable to detect the signal near *CDCA7* described in the 344 past work (rs11683493 (T), p=1.7 x 10⁻⁸). In our analysis using the NFBC66 GWAS data, 9.44 past work (rs11683493 (T), $p=1.7 \times 10^{-8}$). In our analysis using the NFBC66 GWAS data, 345 this variant showed a p-value of 0.09 and therefore, the resulting p-value from the meta-345 this variant showed a p-value of 0.09 and therefore, the resulting p-value from the meta-
346 analysis remained below the threshold of significance (p=1.02 x 10⁻⁵). Although there might 346 analysis remained below the threshold of significance (p=1.02 x 10⁻⁵). Although there might 347 be various sources of variability which explains this discrepancy in our findings, we 347 be various sources of variability which explains this discrepancy in our findings, we 348 bypothesise the difference in sample size to be the primary reason. hypothesise the difference in sample size to be the primary reason.

³⁴⁹**Gene set and tissue set enrichment analysis**

350 Gene set enrichment analysis highlighted significant enrichment of renal system vasculature
351 morphogenesis (p=5.2x10⁻⁸), glomerulus vasculature morphogenesis (p=1.77x10⁻⁷) and 351 morphogenesis (p=5.2x10⁻⁸), glomerulus vasculature morphogenesis (p=1.77x10⁻⁷) and
352 glomerulus morphogenesis (p=2.99x10⁻⁶) (see Supplementary Table 4 and Supplementary 352 glomerulus morphogenesis (p=2.99x10⁻⁶) (see Supplementary Table 4 and Supplementary 353 Figure 2). Tissue expression analysis vielded the strongest enrichment in the pituitary gland. 353 Figure 2). Tissue expression analysis yielded the strongest enrichment in the pituitary gland, 354 even though not reaching significance after multiple testing correction (p_{ponedi}=0.02) (see 354 even though not reaching significance after multiple testing correction ($p_{\text{non-adj}}$ =0.02) (see 355 Supplementary Figure 2). Supplementary Figure 2 and Supplementary Table 5 and Supplementary Figure 2).

356

357

³⁵⁸**Supplementary Figure 2. Gene set and tissue set enrichment results. A) Gene set** 359 **enrichment analyses with MAGMA.** Green bars and the red dashed line indicate 360 Bonferroni threshold, set to $p=0.05/15485=3.22 \times 10^6$. **B) Tissue enrichment analyses** Bonferroni threshold, set to p=0.05/15485=3.22 x 10⁻⁶. **B) Tissue enrichment analyses** 361 with MAGMA. Red dashed line indicates Bonferroni threshold, set to p=0.05/54=0.0009. with MAGMA. Red dashed line indicates Bonferroni threshold, set to p=0.05/54=0.0009.

³⁶³**Genetic correlations of AMH levels with diseases and traits**

364 From genetic correlation analysis assessing the relationship between AMH levels and 1,335
365 traits (summary statistics for those traits are found in http://www.nealelab.is/uk-biobank/). 365 traits (summary statistics for those traits are found in http://www.nealelab.is/uk-biobank/),
366 three traits reflecting menopausal timing remained significant after FDR correction, all 366 three traits reflecting menopausal timing remained significant after FDR correction, all 367 displaying very high genetic correlations with AMH levels: 'Age at menopause' $(r_a=0.95,$ 367 displaying very high genetic correlations with AMH levels: 'Age at menopause' (r_g=0.95,
368 = se=0.21 = n=8.85 x 10⁻⁶) . 'Had menopause' (referring to baying already undergone se=0.21, p=8.85 x 10-6 ³⁶⁸), 'Had menopause' (referring to having already undergone 369 menopause) (r_g=-0.99, se=0.22, p=1.56 x 10⁻⁵) and 'Age started hormone-replacement
370 therapy (HRT)' (age for initiation of chormone replacement therapy) (r.=0.92, se=0.21 370 therapy (HRT)' (age for initiation of hormone replacement therapy) ($r_g=0.92$, se=0.21, 371 p=2.05 x 10⁻⁵). Additionally, we observed a range of nominally significant associations $p=2.05 \times 10^{-5}$). Additionally, we observed a range of nominally significant associations
372 (p<0.05) with traits spanning reproductive/hormonal traits (such as polyp of female genital 372 (p<0.05) with traits spanning reproductive/hormonal traits (such as polyp of female genital
373 tract and female genital prolapse), metabolic traits such as inverse relationship with HbA1c tract and female genital prolapse), metabolic traits such as inverse relationship with HbA1c

374 and positive correlations with neoplasms such as breast and bowel cancer. (Supplementary 375 Figure 3 and full results and details can be found in Supplementary Figure 3 and full results and details can be found in Supplementary Table 6).

376

³⁷⁷**Supplementary Figure 3. Genetic correlation results between AMH summary statistics** ³⁷⁸**and publicly available summary statistics for other traits.** Out of 1,335 associations, the 379 lower section depicts significant associations after FDR correction (p-adj<0.05) and the 380 upper section depicts nominal significant correlations (p<0.05). Dots show the estimated 380 upper section depicts nominal significant correlations (p<0.05). Dots show the estimated
381 qenetic correlation (rg) and error bars indicate 95% confidence limits. Dotted red line 381 genetic correlation (rg) and error bars indicate 95% confidence limits. Dotted red line
382 Lindicates no genetic correlation. ICD10: International Classifications of Diseases 10th 382 indicates no genetic correlation. ICD10: International Classifications of Diseases 10th
383 Revision. Revision.

³⁸⁴**Phenome-wide association study**

385 To get more insights into phenotypic manifestations of the AMH-associated variants, we
386 Derformed a phenome-wide association study using the GWAS Catalog. We detected that 386 performed a phenome-wide association study using the GWAS Catalog. We detected that 387 associated variants in the six loci identified had associations across several traits, spanning 387 associated variants in the six loci identified had associations across several traits, spanning
388 from cardiovascular traits, age at menopause, estradiol levels, heel bone mineral density, 388 from cardiovascular traits, age at menopause, estradiol levels, heel bone mineral density, 389 breast cancer, uterine fibroids, PCOS to blood cell counts (Supplementary Table 7 and 389 breast cancer, uterine fibroids, PCOS to blood cell counts (Supplementary Table 7 and 390 Supplementary Figure 3). Supplementary Figure 3).

391 We performed a further look-up of the lead variants in the FinnGen study (data freeze 9, total 392 n=377,277), which combines samples collected from Finnish biobanks to digital health care $n=377,277$), which combines samples collected from Finnish biobanks to digital health care
393 data. We detected that two of the lead variants had associations (p<1 x 10⁻⁵) with outcomes data. We detected that two of the lead variants had associations (p<1 x 10⁻⁵) with outcomes 394 in FinnGen, rs762643 (near *BMP4*) associated with cervical disc disorders and hernia, while 394 in FinnGen, rs762643 (near *BMP4*) associated with cervical disc disorders and hernia, while
395 strat 86430430 (near *CHEK2*) associated with a variety of outcomes including diseases of the ³⁹⁵rs186430430 (near *CHEK2*) associated with a variety of outcomes including diseases of the

396 genitourinary tract, different neoplasms (e.g. leiomyoma of uterus, neoplasms of ovary), and 397 breast-cancer-related outcomes (full results can be found in Supplementary Table 8). breast-cancer-related outcomes (full results can be found in Supplementary Table 8).

398

Supplementary Figure 4. River plot showing the association between lead variants (or variants in high LD with these) identified in our AMH GWAS (left column) and independent traits which show significant association results for respective variants in the GWAS Catalog (right column).

⁴⁰⁴**DISCUSSION**

405 Our GWAS meta-analysis of circulating AMH measurements in 9,668 pre-menopausal
406 women, including 2,619 measurements from women at age 31 vears old from the 406 women, including 2,619 measurements from women at age 31 years old from the 407 Network and CHEK2. ⁴⁰⁷NFBC1966, identified three novel association signals near *EIF4EBP1*, *BMP4* and *CHEK2*. ⁴⁰⁸We also detected three previously identified signals near *TEX41*, *MCM8*, and *AMH* ⁴⁰⁹(Verdiesen *et al.*, 2022).

⁴¹⁰*CHEK2* was one of the most interesting associated loci. Of note, the lead variant near 411 *CHEK*2 (rs186430430, p=9.69 × 10⁻¹¹, MAF= 0.002) is in complete linkage disequilibrium
412 *(r²=*1) with a frameshift variant is 1100delC (rs555607708, found in NEBC GWAS only 412 (r^2 =1) with a frameshift variant, c.1100delC (rs555607708, found in NFBC GWAS only,
413 $p=6.69 \times 10^{-05}$. OR=1.87, 95% Cl= 1.37-2.55), as it is enriched in the Finnish population 413 $p=6.69 \times 10^{-05}$, OR=1.87, 95% CI= 1.37-2.55), as it is enriched in the Finnish population
414 (MAF=0.008) compared to other non-Finnish and non-Estonian European populations 414 (MAF=0.008) compared to other non-Finnish and non-Estonian European populations
415 (MAF=0.002) (Tyrmi et al., 2022). Apart from being known as a moderate risk gene for ⁴¹⁵(MAF=0.002) (Tyrmi *et al.*, 2022). Apart from being known as a moderate risk gene for 416 breast cancer, different GWA studies highlighted loss of function alleles in *CHEK2* to be
417 associated with firstly, PCOS (Tyrmi et al., 2021) and secondly, with ovarian ageing 417 associated with firstly, PCOS (Tyrmi *et al.*, 2021) and secondly, with ovarian ageing
418 (assessed as age at natural menopause) (Ruth *et al.*, 2021). Furthermore, recent research 418 (assessed as age at natural menopause) (Ruth *et al.*, 2021). Furthermore, recent research
419 done with exome data has also identified an association between *CHEK*2 truncating variants 419 done with exome data has also identified an association between *CHEK2* truncating variants 420
420 (excluding c.1110delC) and later age at menarche (Kentistou *et al.*, 2023). ⁴²⁰(excluding c.1110delC) and later age at menarche (Kentistou *et al.*, 2023).

⁴²¹*CHEK2* encodes a checkpoint kinase 2, which induces cell cycle arrest and apoptosis in 422 response to DNA damage (Ahn *et al.*, 2004), also in oocytes with unrepaired DNA damage
423 (Ruth *et al.*, 2021). In the work from *Ruth et al.*, 2021 Chek2-/- female mice showed reduced ⁴²³(Ruth *et al.*, 2021). In the work from *Ruth et al.,* ²⁰²¹ Chek2-/- female mice showed reduced follicular atresia around reproductive senescence, increased follicular response to

425 gonadotrophin stimulation, and also elevated AMH levels around reproductive senescence.
426 Our finding goes in line with this research and supports the hypothesis that loss of function in 426 Our finding goes in line with this research and supports the hypothesis that loss of function in
427 CHEK2 might result in decreased follicular atresia and higher AMH levels also in voung ⁴²⁷*CHEK2* might result in decreased follicular atresia and higher AMH levels also in young premenopausal women.

429 In our general meta-analysis, we also detected previously identified associations of a
430 missense variant in MCM8 (Ruth et al., 2019; Verdiesen et al., 2022), a known DNA repair ⁴³⁰missense variant in *MCM8* (Ruth *et al.*, 2019; Verdiesen *et al.*, 2022), a known DNA repair 431 gene (Park *et al.*, 2013). This missense variant has been associated previously with 432 premature ovarian failure, infertility, age at menopause (Day et al., 2015) and cancer 432 premature ovarian failure, infertility, age at menopause (Day *et al.*, 2015) and cancer
433 (Michailidou *et al.*, 2017: Griffin and Trakselis, 2019: Lutzmann et al., 2019). However, this ⁴³³(Michailidou *et al.*, 2017; Griffin and Trakselis, 2019; Lutzmann *et al.*, 2019). However, this 434 association was the weakest in NFBC66 alone. While this could support an age-specific
435 effect of the missense variant, as supported in Verdiesen et al. upon identifying a negative 435 effect of the missense variant, as supported in Verdiesen *et al*. upon identifying a negative
436 effect direction for the cohort including adolescents versus older cohorts, this discrepancy 436 effect direction for the cohort including adolescents versus older cohorts, this discrepancy
437 might be as well due to the variant's lower frequency in the Finnish population (MAF=0.02 437 might be as well due to the variant's lower frequency in the Finnish population (MAF=0.02
438 compared to MAF=0.06 in other European populations) and a smaller sample size in the 438 compared to MAF=0.06 in other European populations) and a smaller sample size in the
439 DEBC1966 study Eurther research including age-stratified groups with AMH levels available 439 NFBC1966 study. Further research including age-stratified groups with AMH levels available
440 and genetic data might inform potential age-specific effects of genetic signals. and genetic data might inform potential age-specific effects of genetic signals.

441
442

⁴⁴²Regarding the missense variant in the AMH gene also reported in Verdiesen *et al*., the 443 association between the missense variant rs10417628 in the *AMH* gene and AMH levels
444 Fremains unclear in the current analysis. A case report from 2020 suggested that this variant 444 Femains unclear in the current analysis. A case report from 2020 suggested that this variant 445 reduces AMH detection without affecting its bioactivity (Hoyos et al., 2020). Previous GWAS 445 reduces AMH detection without affecting its bioactivity (Hoyos *et al.*, 2020). Previous GWAS
446 meta-analysis also provided inconclusive results due to inconsistent evidence from different 446 meta-analysis also provided inconclusive results due to inconsistent evidence from different 447 assay data. In the NFBC66 study using an automated assay (Elecsys® AMH Plus), the 447 assay data. In the NFBC66 study using an automated assay (Elecsys® AMH Plus), the
448 unissense variant showed a p-value of 0.15 (n=2.619), supporting the hypothesis of a 448 missense variant showed a p-value of 0.15 (n=2,619), supporting the hypothesis of a
449 detection issue rather than an actual difference in AMH bioactivity. However, comparing 449 detection issue rather than an actual difference in AMH bioactivity. However, comparing
450 AMH values from different assavs remains problematic. and recent evidence suggests lower 450 AMH values from different assays remains problematic, and recent evidence suggests lower
451 values in automated assays compared to Gen II and Ansh Labs assay (Moolhuijsen and 451 values in automated assays compared to Gen II and Ansh Labs assay (Moolhuijsen and
452 Visser, 2020). Further research is needed to validate the association between rs10417628 452 Visser, 2020). Further research is needed to validate the association between rs10417628
453 and AMH levels using different assavs. and AMH levels using different assays.

454 Colocalization analysis supports regulatory effects of GWAS variants associated with AMH
455 with genetic variants modifying expression levels of TEX41, BMP4 and EIF4EBP1 and thus ⁴⁵⁵with genetic variants modifying expression levels of *TEX41*, *BMP4* and *EIF4EBP1* and thus 456 provides a refinement for the characterization of possible regulatory effects of the genetic 457 variants on different transcripts and genes variants on different transcripts and genes.

458 Interestingly, we observed high posterior probability (PP4=0.99) of colocalization between
459 our GWAS signal and eQTL signal for the *TEX41* (Testis expressed 41) transcript 459 our GWAS signal and eQTL signal for the *TEX41* (Testis expressed 41) transcript 460 ENST00000414256 in the testis. prioritising this long non-coding RNA gene for the first time 460 ENST00000414256 in the testis, prioritising this long non-coding RNA gene for the first time
461 in association with AMH levels based on colocalization analysis. In the same locus, ZEB2 ⁴⁶¹in association with AMH levels based on colocalization analysis. In the same locus*, ZEB2* 462 shows biological plausibility as a candidate gene since it plays a role as inhibitor of signal
463 transduction in TGF-B and BMP signalling through interaction with ligand-activated SMAD 463 transduction in TGF-B and BMP signalling through interaction with ligand-activated SMAD
464 proteins (Postigo et al., 2003; Conidi et al., 2011). ⁴⁶⁴proteins (Postigo *et al.*, 2003; Conidi *et al.*, 2011).

⁴⁶⁵Colocalization analysis also supported the nomination of *EIF4EBP1* in the novel locus 466 identified in chromosome 8. This gene encodes a translation repressor protein that 467 competitively binds to eukaryotic translation initiation factor 4E (EIF4E) (Gingras et al., 1999; 467 competitively binds to eukaryotic translation initiation factor 4E (EIF4E) (Gingras *et al.*, 1999;
468 Harris and Lawrence, 2003) and is a maior substrate of mTOR and a key player in mTOR 468 Harris and Lawrence, 2003) and is a major substrate of mTOR and a key player in mTOR
469 Signalling pathway. Studies show that both EIF4EBP1 and EIF4E are involved in cancer 469 signalling pathway. Studies show that both EIF4EBP1 and EIF4E are involved in cancer
470 development and progression where up-regulated EIF4E plays an oncogenic role in development and progression where up-regulated EIF4E plays an oncogenic role in

471 carcinogenesis (Heikkinen *et al.*, 2013; Cha *et al.*, 2015). The same intergenic lead variant in
472 this locus has been associated with age at menopause, and other menopause-related traits 472 this locus has been associated with age at menopause, and other menopause-related traits
473 (ever had menopause and ever used hormone-replacement therapy), supporting a plausible 473 (ever had menopause and ever used hormone-replacement therapy), supporting a plausible
474 association with AMH levels. association with AMH levels.

475 We observed colocalization between our GWAS signal and variants modulating gene
476 expression of *BMP4. BMP4* has a known regulatory role on AMH expression through 476 expression of *BMP4. BMP4* has a known regulatory role on AMH expression through 477 activation of the SMAD proteins (Estienne et al., 2015). *Pierre et al.*, 2016). Smad interacting 477 activation of the SMAD proteins (Estienne *et al.*, 2015; Pierre *et al.*, 2016). Smad interacting
478 protein 1 (also known as *ZEB2*) is one of the plausible candidate genes in chromosome 2. 478 protein 1 (also known as *ZEB2)* is one of the plausible candidate genes in chromosome 2,
479 which would as well interact with SMAD proteins and participate in AMH regulation (Postigo 479 which would as well interact with SMAD proteins and participate in AMH regulation (Postigo 480 et al., 2003). ⁴⁸⁰*et al.*, 2003).

481 Our GWAS of AMH measurements revealed significant enrichment in renal system vascular
482 – morphogenesis, glomerulus vascular morphogenesis, and glomerulus morphogenesis gene 482 morphogenesis, glomerulus vascular morphogenesis, and glomerulus morphogenesis gene
483 set analysis. This supports the close connection between urinary and reproductive system 483 set analysis. This supports the close connection between urinary and reproductive system
484 development, originating from a common embrvological origin, the intermediate mesoderm. 484 development, originating from a common embryological origin, the intermediate mesoderm.
485 Additionally, in our gene set enrichment results, we observed a nominal significance 485 Additionally, in our gene set enrichment results, we observed a nominal significance
486 association with the gonadal mesoderm gene set (p=4.2 \times 10⁻⁵), further supporting the 486 association with the gonadal mesoderm gene set (p=4.2 \times 10⁻⁵), further supporting the 487 interconnectedness of the urinary and reproductive systems during development. We 487 interconnectedness of the urinary and reproductive systems during development. We
488 propose that this observation may be linked to the identification of BMP4 locus associated 488 bropose that this observation may be linked to the identification of *BMP4* locus associated
489 b with AMH levels. The BMP4 signalling pathway is crucial during kidney development. 489 with AMH levels. The BMP4 signalling pathway is crucial during kidney development,
490 including ureteric bud outgrowth (Grinspon and Rev. 2014: Nishinakamura and Sakaguchi. 490 including ureteric bud outgrowth (Grinspon and Rey, 2014; Nishinakamura and Sakaguchi,
491 12014: Oxburgh *et al.*, 2014). This observation suggests that genetic variants affecting the 491 2014; Oxburgh *et al.*, 2014). This observation suggests that genetic variants affecting the 492 renal system's development and function could influence AMH levels in women later in life. 492 Fenal system's development and function could influence AMH levels in women later in life.
493 To gain further insight, studving AMH levels in younger cohorts and conducting sex-stratified 493 To gain further insight, studying AMH levels in younger cohorts and conducting sex-stratified
494 Analyses may be valuable in understanding the association between urogenital development 494 analyses may be valuable in understanding the association between urogenital development
495 and AMH levels in postnatal stages. and AMH levels in postnatal stages.

496 Tissue expression analysis also identified enrichment in the pituitary gland, although this did
497 not reach significance after multiple testing correction. This result goes in line with research 497 bot reach significance after multiple testing correction. This result goes in line with research
498 btrom recent vears showing that AMH bas versatile actions in different levels of the 498 from recent years showing that AMH has versatile actions in different levels of the
499 hypothalamus-pituitary-gonadal axis (Silva and Giacobini, 2021), further supporting the 499 bypothalamus-pituitary-gonadal axis (Silva and Giacobini, 2021), further supporting the 4000 developmental alterations of neuroendocrine circuits requilation dertility. developmental alterations of neuroendocrine circuits regulating fertility.

501 We identified three significant genetic correlations which align with the observations in
502 Verdiesen et al., indicating a strong positive genetic correlation between AMH and traits 502 Verdiesen et al., indicating a strong positive genetic correlation between AMH and traits
503 Freflecting age at menopause, suggesting shared underlying genetic risk factors and 503 reflecting age at menopause, suggesting shared underlying genetic risk factors and
504 supporting AMH as a proxy for ovarian reserve. We also found interesting nominal significant 504 supporting AMH as a proxy for ovarian reserve. We also found interesting nominal significant
505 associations. pointing towards a shared genetic background between AMH levels and breast 505 associations, pointing towards a shared genetic background between AMH levels and breast
506 cancer, consistent with epidemiological studies (Ge et al., 2018). We hypothesise both 506 cancer, consistent with epidemiological studies (Ge *et al.*, 2018). We hypothesise both 507 S507 MCM8 and CHEK2 loci may play a role in this relationship and MCM8 and CHEK2 loci may play a role in this relationship an ⁵⁰⁷*MCM8* and *CHEK2* loci may play a role in this relationship and Mendelian randomisation studies with independent samples could further investigate this association's direction.

509 Upon querying the AMH GWAS lead variants and variants in high linkage disequilibrium with 510 those in other traits, we found shared significant signals amongst known epidemiological 510 those in other traits, we found shared significant signals amongst known epidemiological
511 associations (Homburg and Crawford, 2014; De Kat et al., 2017; Ge et al., 2018; 511 associations (Homburg and Crawford, 2014; De Kat *et al.*, 2017; Ge *et al.*, 2018;
512 Moolhuijsen and Visser, 2020) with AMH such as PCOS, breast cancer, postmenopausal 512 Moolhuijsen and Visser, 2020) with AMH such as PCOS, breast cancer, postmenopausal
513 status (age at menopause, estradiol levels, heel bone mineral density) and cardiovascular 513 status (age at menopause, estradiol levels, heel bone mineral density) and cardiovascular
514 disease. Additionally, we observed novel associations with other traits in European ancestry 514 disease. Additionally, we observed novel associations with other traits in European ancestry
515 studies. including uterine fibroids (coming from signal in *MCM8*) and blood cell counts 515 studies, including uterine fibroids (coming from signal in *MCM8*) and blood cell counts
516 (coming from signals near *CHEK2*, which has been also associated recently with clonal 516 (coming from signals near *CHEK2*, which has been also associated recently with clonal
517 hematopoiesis (Kar *et al.*, 2022). Further epidemiological studies assessing the potential hematopoiesis (Kar *et al.*, 2022). Further epidemiological studies assessing the potential

518 causal relationships between these traits and AMH levels are warranted to better understand 519 the mechanisms underlying these associations. the mechanisms underlying these associations.

520 Our study has several strengths, including a large sample size and inclusion of a founder
521 population, which allowed us to identify novel rare variants associated with AMH levels. 521 population, which allowed us to identify novel rare variants associated with AMH levels.
522 Furthermore a vounger cohort and equal age of measurement from 2.619 women increases 522 Furthermore, a younger cohort and equal age of measurement from 2,619 women increases
523 the variability of AMH levels and boosts the power to detect associations. We also performed 523 the variability of AMH levels and boosts the power to detect associations. We also performed
524 colocalization analysis for the first time, which provides a refinement for the characterization 524 colocalization analysis for the first time, which provides a refinement for the characterization
525 of possible regulatory effects of the genetic variants on different transcripts and genes and 525 of possible regulatory effects of the genetic variants on different transcripts and genes and
526 detect significant gene set enrichment. Our study has some limitations to consider. First, we 526 detect significant gene set enrichment. Our study has some limitations to consider. First, we
527 only included women of European ancestry, and our findings may not be generalizable to 527 only included women of European ancestry, and our findings may not be generalizable to
528 other populations. Second, as with other reproductive phenotypes, the lack of sufficiently 528 other populations. Second, as with other reproductive phenotypes, the lack of sufficiently
529 sized datasets from relevant tissue in commonly used gene expression databases hinders a 529 sized datasets from relevant tissue in commonly used gene expression databases hinders a
530 more reliable assessment of the mechanisms underlying regulatory effects in reproductive 530 more reliable assessment of the mechanisms underlying regulatory effects in reproductive
531 tissues. tissues.

532 In conclusion, our study expands our understanding of the genetic determinants of serum
533 AMH levels in pre-menopausal women by identifying new loci associated with serum AMH 533 AMH levels in pre-menopausal women by identifying new loci associated with serum AMH
534 Concentration. Our results highlight the increased power of founder populations and larger 534 concentration. Our results highlight the increased power of founder populations and larger
535 sample sizes to boost the discovery of novel trait-associated variants underlying variation in 535 sample sizes to boost the discovery of novel trait-associated variants underlying variation in
536 AMH levels and to explore plausible genetic regulatory effects of the variants identified. 536 AMH levels and to explore plausible genetic regulatory effects of the variants identified.
537 Further studies are needed to validate our findings and to explore the biological mechanisms 537 Further studies are needed to validate our findings and to explore the biological mechanisms
538 Underlying the identified associations. underlying the identified associations.

⁵⁴⁰**Acknowledgments**

- 541 We want to thank the participants and investigators of the FinnGen study and the NFBC1966
542 Study. Part of the computations were performed in the High-Performance Computing Center
- 542 study. Part of the computations were performed in the High-Performance Computing Center
543 of University of Tartu.
- of University of Tartu.

⁵⁴⁵**Bibliography**

- ⁵⁴⁶Ahn J, Urist M, Prives C. The Chk2 protein kinase. *DNA Repair (Amst)* [Internet] ⁵⁴⁷2004;**3**:1039–1047. DNA Repair (Amst).
- 548 Bulik-Sullivan B, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ, Price AL, 549 Neale BM. Corvin A, et al. LD score regression distinguishes confounding from 549 **Neale BM, Corvin A,** *et al.* **LD score regression distinguishes confounding from**
550 polygenicity in genome-wide association studies. Nat Genet 2015:47:291–295. 550 polygenicity in genome-wide association studies. *Nat Genet* 2015;47:291–295. Nature
551 Publishing Group.
- 551 Publishing Group.
552 Cha YL. Li PD. Yuan L. 552 Cha YL, Li PD, Yuan LJ, Zhang MY, Zhang YJ, Rao HL, Zhang HZ, Zheng XFS, Wang HY.
553 EIF4EBP1 overexpression is associated with poor survival and disease progression in 553 EIF4EBP1 overexpression is associated with poor survival and disease progression in
554 patients with hepatocellular carcinoma. PLoS One Internet1 2015:10:. PLoS One.
- 554 patients with hepatocellular carcinoma. *PLoS One* [Internet] 2015;**10**:. PLoS One.
555 Conidi A. Cazzola S. Beets K. Coddens K. Collart C. Cornelis F. Cox L. Joke D. Dobre 555 Conidi A, Cazzola S, Beets K, Coddens K, Collart C, Cornelis F, Cox L, Joke D, Dobreva
556 MP. Dries R. *et al.* Few Smad proteins and many Smad-interacting proteins vield 556 MP, Dries R, *et al.* Few Smad proteins and many Smad-interacting proteins yield
557 multiple functions and action modes in TGFß/BMP signaling in vivo. Cytokine Gro 557 multiple functions and action modes in TGFβ/BMP signaling in vivo. *Cytokine Growth* **Factor Rev.** Comment **Factor Rev.** Comment **Proment Crowth Factor Rev.** Comment **Proment Crowth Factor Rev.** Comment **Proment C**
- ⁵⁵⁸*Factor Rev* [Internet] 2011;**22**:287–300. Cytokine Growth Factor Rev. 559 Day FR, Ruth KS, Thompson DJ, Lunetta KL, Pervjakova N, Chasman DI, Stolk L, Finucane
560 HK, Sulem P, Bulik-Sullivan B, et al. Large-scale genomic analyses link reproductive 560 HK, Sulem P, Bulik-Sullivan B, *et al.* Large-scale genomic analyses link reproductive
561 aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated ⁵⁶¹aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated
- 562 DNA repair. *Nat Genet* [Internet] 2015;47:1294–1303. Nat Genet.
563 Estienne A, Pierre A, Clemente N Di, Picard JY, Jarrier P, Mansanet C Estienne A, Pierre A, Clemente N Di, Picard JY, Jarrier P, Mansanet C, Monniaux D, Fabre

- 674 EBR, Piltonen TT, Laisk T, *et al.* Leveraging Northern European population history;
675 http://www.frequency variants for polycystic ovary syndrome. *medRxiv* [Internet]
- 675 novel low frequency variants for polycystic ovary syndrome. *medRxiv* [Internet]
676 2021:2021.05.20.21257510Available from:
- 676 2021;2021.05.20.21257510Available from:
677 http://medrxiv.org/content/early/2021/05/24
- 677 http://medrxiv.org/content/early/2021/05/24/2021.05.20.21257510.abstract.
678 Tyrmi JS, Arffman RK, Pujol-Gualdo N, Kurra V, Morin-Papunen L, Sliz E, Pilton 678 Tyrmi JS, Arffman RK, Pujol-Gualdo N, Kurra V, Morin-Papunen L, Sliz E, Piltonen TT, Laisk
679 T. Kettunen J. Laivuori H. Leveraging Northern European population history: novel low-679 T, Kettunen J, Laivuori H. Leveraging Northern European population history: novel low-
680 frequency variants for polycystic ovary syndrome. Hum Reprod [Internet] 2022:37:352-⁶⁸⁰frequency variants for polycystic ovary syndrome. *Hum Reprod* [Internet] 2022;**37**:352– ⁶⁸¹365. Hum Reprod.
- 682 Verdiesen RMG, Schouw YT Van Der, Gils CH Van, Verschuren WMM, Broekmans FJM,
683 Borges MC, Goncalves Soares AL, Lawlor DA, Fliassen AH, Kraft P, et al, Genome-683 Borges MC, Gonçalves Soares AL, Lawlor DA, Eliassen AH, Kraft P, *et al.* Genome-684 wide association study meta-analysis identifies three novel loci for circulating anti-
685 Müllerian hormone levels in women. Hum Reprod Ilnternet1 2022:37:1069–1082. ⁶⁸⁵Müllerian hormone levels in women. *Hum Reprod* [Internet] 2022;**37**:1069–1082.
-
- 686 **Oxford University Press.**
687 Watanabe K, Taskesen E, Bo 687 Watanabe K, Taskesen E, Bochoven A van, Posthuma D. Functional mapping and
688 annotation of genetic associations with FUMA. Nat Commun 2017;8:1826. ⁶⁸⁸annotation of genetic associations with FUMA. *Nat Commun* 2017;**8**:1826.
- 689 Weenen C, Laven JSE, Bergh ARM von, Cranfield M, Groome NP, Visser JA, Kramer P, 690
690 Fauser BCJM, Themmen APN, Anti-Müllerian hormone expression pattern in the
- 690 Fauser BCJM, Themmen APN. Anti-Müllerian hormone expression pattern in the
691 human ovary: potential implications for initial and cyclic follicle recruitment. Mol H 691 human ovary: potential implications for initial and cyclic follicle recruitment. *Mol Hum* **692 Reprod Internet** 2004:10:77–83. Mol Hum Reprod.
- ⁶⁹²*Reprod* [Internet] 2004;**10**:77–83. Mol Hum Reprod.
-

with MAGMA Gene set enrichment

ICD10: N84 Polyp of female genital tract ICD10: N81 Female genital prolapse Ever used hormone-replacement therapy (HRT) Age of primiparous women at birth of child Age first had sexual intercourse Urea Pain type experienced in last month: Headache ICD10: M51 Other intervertebral disk disorders ICD10: E04 Other non-toxic goitre Heel bone mineral density (BMD) Worrier / anxious feelings Age at first episode of depression Triglycerides Treatment: lisinopril+hydrochlorothiazide Glycated haemoglobin (HbA1c) Arm fat-free mass (left) Malignant neoplasm of breast Illnesses of mother: Bowel cancer Had menopause Age started hormone-replacement therapy (HRT) Age at menopause (last menstrual period)

Blood cell counts

Cancer

Cardiovascular disease

Menopause related trait

Reproductive traits

